Optimizing Clinical Practice in Prostate Cancer (video series) +... +

Optimizing Clinical Practice in Prostate Cancer Advanced prostate cancer (PC) includes metastatic hormone-sensitive PC (mHSPC), nonmetastatic castration-resistant PC (nmCRPC), and metastatic castration-resistant PC (mCRPC). Management of these disease types differs, but the overall goal when treating them is the same: to prolong life, to delay disease progression, and to maintain quality of life for patients by minimizing symptoms. This Learning Center will focus on understanding the latest data in advanced PC, including innovations in androgen receptor-targeted (ART) therapy, radiopharmaceuticals, how to interpret the data for clinical practice, and what impact this may have on clinical decision-making and aligning treatment for the individual patient. https://www.medscape.org/advances/optimizing-clinical-practice-prostate-cancer-2026a1000jj9?src=mkmcmr_driv_32025_mscpedu_461680.01_ace_final&uac=148436CN The New Era of mHSPC Treatment: Evaluating Emerging Doublet and Triplet Combinations Authors: Neal D. Shore, MD, FACS; Sarah Caulfield, PharmD, BCOP; Rana R. McKay, MD, FASC https://www.medscape.org/viewarticle/new-era-mhspc-treatment-evaluating-emerging-doublet-and-2026a1000kt7?page=1&src=mkmcmr_driv_32025_mscpedu_461680.01_ace_final&uac=148436CN